Literature DB >> 10898706

Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.

B Heinemann1, H Wisplinghoff, M Edmond, H Seifert.   

Abstract

In vitro activities of seven fluoroquinolones against 140 clinical Acinetobacter baumannii isolates representing 138 different strain types were determined. The rank order of activity was clinafloxacin > gatifloxacin > levofloxacin > trovafloxacin > gemifloxacin = moxifloxacin > ciprofloxacin. The 31 outbreak-related A. baumannii strains were significantly more resistant than were 109 sporadic strains.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898706      PMCID： PMC90044          DOI： 10.1128/AAC.44.8.2211-2213.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 2.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

3.  In-vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones.

Authors:  A Pascual; I López-Hernández; L Martínez-Martínez; E J Perea
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Comparison of ribotyping and pulsed-field gel electrophoresis for molecular typing of Acinetobacter isolates.

Authors:  H Seifert; P Gerner-Smidt
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

Review 8.  Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

Authors:  L J Piddock
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  Plasmid DNA profiles of Acinetobacter baumannii: clinical application in a complex endemic setting.

Authors:  H Seifert; B Boullion; A Schulze; G Pulverer
Journal:  Infect Control Hosp Epidemiol       Date:  1994-08       Impact factor: 3.254

10.  Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; J Ruiz; P Goñi; A Marcos; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  6 in total

Review 1.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

2.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 3.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 4.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.

Authors:  Pirkko Kotilainen; Susa Pitkänen; Anja Siitonen; Pentti Huovinen; Antti J Hakanen
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-05       Impact factor: 3.944

Review 6.  Spatio-Temporal Distribution of Acinetobacter baumannii in Germany-A Comprehensive Systematic Review of Studies on Resistance Development in Humans (2000-2018).

Authors:  Gamal Wareth; Christian Brandt; Lisa D Sprague; Heinrich Neubauer; Mathias W Pletz
Journal:  Microorganisms       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.